Back HCV Treatment

HCV Treatment

2. Harvoni and Viekira Pak: Effective Oral Combinations for HCV Genotype 1

2014 saw the long-awaited U.S. Food and Drug Administration (FDA) approval of new interferon-free combination regimens for people with genotype 1 chronic hepatitis C: Gilead Sciences sofosbuvir/ledipasvir coformulation (Harvoni) in October and AbbVie's paritaprevir/ritonavir/ombitasvir plus dasabuvir regimen (Viekira Pak, formerly known as "3D") in late December. 

alt

Read more:

3. High Hepatitis C Treatment Cost Leads to Restrictions, Sets Off Price War

The high cost of new interferon-free hepatitis C treatments has raised concerns about how public payers and private insurers will be able to afford them and sparked a more general discussion about the cost of pharmaceuticals in a changing healthcare landscape.

alt

Read more:

Updated Hepatitis C Treatment Guidelines Add New Therapies, Hard-to-Treat Patients

The American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA), and International Antiviral Society-USA (IAS-USA) recently updated their hepatitis C treatment guidelines to add newly approved interferon-free direct-acting antiviral regimens and to provide more information about treating patients with HIV/HCV coinfection and decompensated liver disease. The evolving guidelines are available online at HCVguidelines.org.

alt

Read more:

9. Evolving Hepatitis C Therapy Guidelines and Treatment Cascade

The first U.S. hepatitis C treatment guidelines incorporating interferon-free direct-acting antiviral regimens were issued in January 2014 and periodically updated to reflect new drug approvals and emerging data from studies and real-world use. The new therapies have cure rates above 90%, but cost and other barriers have limited their use.

alt

Read more:

AASLD 2014: ACH-3102 plus Sofosbuvir Cures All Hepatitis C Patients in Phase 2 Study

Achillion's second-generation HCV NS5A inhibitor ACH-3102 combined with sofosbuvir (Sovaldi) was well-tolerated and led to sustained virological response in all treatment-naive genotype 1 hepatitis C patients in a Phase 2 proxy study, according to late-breaking findings presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meetinglast month in Boston. Another early study showed promising results for Achillion's nucleotide polymerase inhibitor ACH-3422.

alt

Read more: